Scholar Rock Holding Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 3, 2024, reports on clinical trial data presented by Scholar Rock Holding Corp. at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. The filing focuses on the Phase 1 DRAGON proof-of-concept trial evaluating SRK-181 in combination with pembrolizumab for patients with advanced solid tumors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding clinical progress and does not contain financial statements.
Material Changes and Clinical Data
The primary material update is the release of new safety and efficacy data from the dose expansion phase (Part B) involving 78 patients treated with 1500 mg of SRK-181 every three weeks.
- Safety Profile: SRK-181 was generally well tolerated. One Grade 4 treatment-related adverse event (generalized dermatitis exfoliative) was observed. No Grade 5 treatment-related adverse events occurred. The most common adverse events were rash, pruritus, fatigue, and diarrhea.
- Efficacy by Tumor Type: Encouraging responses were observed across multiple cohorts. Non-small cell lung cancer (NSCLC) showed no response and was excluded from the summary table.
| Tumor Type | Patient Count (n) | Objective Response Rate (ORR) | Median Durability of Response (months) |
|---|---|---|---|
| Clear Cell Renal Cell Carcinoma (ccRCC) | 30 | 23.3% (7 patients) | 7.7+ (range: 2.5+ to 20.9+) |
| Head and Neck Squamous Cell Carcinoma (HNSCC) | 11 | 18.2% (2 patients) | 2.2+ (range: 0.1 to 4.3+) |
| Melanoma (MEL) | 11 | 27.3% (3 patients) | 4.9 (range: 1.8 to 7.1) |
| Urothelial Carcinoma (UC) | 11 | 9.1% (1 patient) | 12.9 (range: 12.9 to 12.9) |
Outlook, Management Commentary, and Risks
Management highlighted that the combination therapy enhanced the proinflammatory microenvironment, with activated CD8+ T-cells correlating with tumor shrinkage in 6 out of 9 paired biopsies analyzed.
Patient Selection Strategy: The filing identifies potential biomarkers for future patient selection in ccRCC:
- CD8+ Infiltration: Limiting enrollment to patients with baseline CD8+ infiltration could increase ORR to 40% and median durability to 9.3 months.
- Regulatory T-cells (Treg): Limiting enrollment to patients with elevated baseline Treg levels could increase ORR to 50% and median durability to 9.8 months.
A conference call was scheduled for June 4, 2024, to discuss these results. The filing notes that the information is furnished and not "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and presentation slides (Exhibit 99.2) for detailed statistical analysis.
- Confirm the specific definitions of "response" and "durability" used in the RECIST 1.1 assessment.
- Monitor upcoming regulatory filings for updates on the Phase 1 trial design and potential Phase 2 expansion plans based on the biomarker findings.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.